Abstract:Aim To investigate the effect of the target Bcl-2 antisense phosphorothioate oligodeoxynucleotide(AS-PS-ODNs,ASPO) inducing apoptosis and combining with the drugs of chemotherapy on HL60 cell line and 20 cases of primary acute leukemia(AL) cells.Methods The cellular toxicity of HL60 cell line resulted from application of the ASPO or combination with chemotherapeutic drugs was detected by MTT.The expression of Bcl-2 protein was determined by immunocytochemistry.The cell viability and proliferation were tested by Trypan Blue exclusion.The morphologic signs and the DNA ladder of apoptotic cells were observed by acridine orange staining,flow cytometry,transmission electron microscope and DNA fragment electrophoresis.Results ① The ASPO could work in coordination with many chemotherapeutic drugs,including HHRT,VCR,MTX,Ara-c,VP16,ACR and DEX in HL60 cell line.② In presence of the common doses(5 μmol·L-1) of ASPO,12 of 20 of primary ALL in which the suppression ratio of expression of Bcl-2 protein was more than 0.4 were set as group A,and 8 of 20 ones in which the suppression ratio of expression of Bcl-2 protein was lower than 0.4 were set as group B.The apoptotic ratio of group A was higher than that of group B(P0.05),and the apoptotic ratio of both group A and group B was higher than that of control(P0.05).③ The proliferation ratio of primary AL cells in presence of ASPO+Ara-c was suppressed than that of only presence of ASPO,or Ara-c,or plus of them(P0.01).④ The suppression ratio of primary AL cells in presence of ASPO in group A was positively correlated to the redouble time(102.89±37.97) of the growth of primary AL cells(γ=0.577,P0.05).Conclusions Bcl-2 ASPO is a sequence-specific inhibitor of Bcl-2 protein expression of primary AL cells and HL60 cell line.Bcl-2 ASPO is especially suitable for treating ALs which have lower proliferation and higher expression of Bcl-2 protein.The combination of Bcl-2 ASPO with chemotherapeutic drugs has a potential further application for treating the patients with acute leukemia.

Effect of two new bcl-2 antisenses on drug-sensitivity of cells fromn leukemia patients

Effect of Bcl-2 Antisense Oligodeoxynucleotides on Drug Sensitivity of Leukemic Cells

Effect of Bcl-2 Antisense Oligonucleotide Targeting Different Region of Bcl-2 Mrna on Drug-Sensitivity of Leukemia Cells

Bcl-2 Antisense Oligodeoxynucleotide Enhances Araninosyl Cytosine-Induced Apoptosis of Primary Leukemia Cells

Effect of antisense oligodeoxynucleotide targeted against bcl-2 gene on growth and apoptotic susceptibility of leukemia cells

[Design of Antisense Oligodeoxynucleotide Targeting at Bcl-2 Mrna and Observation on Its Effect on the Sensitivity of Leukemia Cells to Arabinosyl Cytosine].

The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia.

Design of Bcl-2 antisense oligodeoxynucleotide and study of its induction apoptosis in K562 cells

Homoharringtonine is Synergistically Lethal with BCL-2 Inhibitor APG-2575 in Acute Myeloid Leukemia

Effect of BcL-2 Antisense Drug with Different Structure on the Biological Function of K562 Cells

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Selection of Effective Bcl-2 Antisense Oligodeoxynucleotides with Computer Software and Experimental Assay

Antisense Oligodeoxynucleotides Inhibit Bcl-2 Expression and Induce Apoptosis in Acute Lymphocytic Leukemia Cells

The Effect of the Target of Bcl-2 Antisense Phosphorothioate Oligodexynucleotides Combined with Chemotherapy on HL60 Cell Line and the Primary Leukemia Cells

Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of HL60 and K562 cells to daunorubicin

The effect of antisense bcl-2 oligonucleotides on bcl-2 protein expression and apoptosis in human colon cancer cells

[The Effects of Antisense Oligonucleotides Bcl-2/Bcl-xl and Bcl-2 on Proliferation and Apoptosis of Breast Cancer Cells].

Bcl-2 antisense therapy in B-cell malignant proliferative disorders

The effect of VEGF antisense oligodeoxynucleotides on apoptosis of leukemia cells

Co‐Targeting C‐myc and Bcl‐2 by Oral Small Molecule Combination of WBC100 and Venetoclax Effectively Controls Acute Myeloid Leukemia in Preclinical Models

[Effects of Antisense Oligodeoxynucleotides Targeting Multidrug Resistance Gene on Resistant Cell Line K562/ AO2].